Patricia Sparks
Psychiatric/Mental Health · Portsmouth, OHNPI 1962560797
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $159,194 of the $210,012 with a category attached, or 75.8%. 19 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 38.0% of the total. 2025 is the largest year on record at $75,558, 6.3 times the $11,954 reported in 2021. Among psychiatric/mental health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 732 payments — averaging $286.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$80K
- AbbVie$34K
- Teva Pharmaceuticals USA, Inc.$30K
- E.r. Squibb & Sons, L.L.C.$23K
- Alkermes, Inc.$20K
- Johnson & Johnson$20K
- plus $3K from 13 others
What the payments were for
- Consulting fees$11,2915%
- Speaking & faculty fees$159,19476%
- Travel & lodging$25,45412%
- Food & beverage$13,8987%
- Education$1760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 186 | $79,903 |
| AbbVie | 148 | $33,941 |
| Teva Pharmaceuticals USA, Inc. | 115 | $29,710 |
| E.r. Squibb & Sons, L.L.C. | 59 | $23,419 |
| Alkermes, Inc. | 57 | $19,962 |
| Johnson & Johnson | 28 | $19,682 |
| Validus Pharmaceuticals LLC | 6 | $795 |
| Otsuka America Pharmaceutical, Inc. | 44 | $766 |
| Axsome Therapeutics, Inc. | 17 | $661 |
| Sunovion Pharmaceuticals Inc. | 40 | $524 |
| Vanda Pharmaceuticals Inc. | 13 | $292 |
| Neurocrine Biosciences, Inc. | 6 | $128 |
| Indivior Inc. | 4 | $93 |
| Lundbeck LLC | 3 | $47 |
| Braeburn Inc. | 2 | $30 |
| Corium, LLC | 1 | $25 |
| Tris Pharma Inc | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$76,617
- LYBALVI$75,752
- VRAYLAR$31,337
- INVEGA SUSTENNA$19,299
- INVEGA TRINZA$19,299
- COBENFY$14,552
- UZEDY$13,875
- Austedo XR$8,035
- AUSTEDO$5,724
- Equetro$668
- Fanapt$125
- SPRAVATO$116
How this compares
$210,012 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 216 | $294,824 |
| Invega TrinzaPaliperidone Palmitate | 12 | $121,974 |
| Invega SustennaPaliperidone Palmitate | 39 | $98,770 |
| CaplytaLumateperone Tosylate | 59 | $91,473 |
| RexultiBrexpiprazole | 50 | $89,229 |
| Risperdal ConstaRisperidone Microspheres | 66 | $71,912 |
| AristadaAripiprazole Lauroxil | 13 | $45,404 |
| AuvelityDextromethorphan Hbr/Bupropion | 29 | $24,157 |
| TrintellixVortioxetine Hydrobromide | 38 | $23,048 |
| Lurasidone Hcl | 33 | $21,787 |
| Paliperidone ErPaliperidone | 90 | $13,155 |
| Clozapine | 299 | $12,440 |
| LinzessLinaclotide | 12 | $10,538 |
| EliquisApixaban | 12 | $7,008 |
| QuviviqDaridorexant Hcl | 12 | $5,986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess | $33,941 | $305,362228 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta | $19,682 | $292,656117 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $79,903 | $91,47359 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $766 | $89,22950 claims |
| Alkermes, Inc.Aristada | $19,962 | $45,40413 claims |
| Axsome Therapeutics, Inc.Auvelity | $661 | $24,15729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Portsmouth
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
- Danielle MorroneCanfield$94K
- Tamara ThornMoraine$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.